Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus.
Blisibimod, an investigational anti-BAFF molecule in Phase III trails for the treatment of systemic lupus erythematosus and Phase II trials for the treatment of IgA nephropathy.